Daily Ards Research Analysis
Analyzed 2 papers and selected 3 impactful papers.
Summary
Two retrospective ICU and perinatal studies refine respiratory care across distinct settings. Genomic surveillance showed low Clostridioides difficile infection (CDI) rates and no transmission among COVID-19 pneumonia/ARDS ICU patients, with whole genome sequencing (WGS) outperforming HMW typing. In late preterm infants of mothers with gestational diabetes, antenatal corticosteroids (ACS) reduced transient tachypnea of the newborn and early mechanical ventilation but did not lower neonatal RDS.
Research Themes
- Genomic epidemiology for ICU infection control during COVID-19/ARDS
- Maternal corticosteroid timing and neonatal respiratory morbidity in GDM
- Methodological advances in retrospective cohorts and negative results
Selected Articles
1. Clostridioides difficile infection in patients with COVID-19 pneumonia - Analysis of occurrence and genetic distribution from three intensive care units.
In three ICUs treating COVID-19 pneumonia/ARDS, CDI occurred in 2.3% (8/343) despite frequent diarrhea, and WGS found no patient-to-patient transmission. WGS outperformed HMW typing for assessing relatedness, underscoring the value of genomic surveillance in ICU infection control.
Impact: This study provides robust negative evidence of CDI transmission in COVID-19 ICU settings and demonstrates the superiority of WGS over HMW typing for outbreak assessment.
Clinical Implications: Maintain CDI prevention and antibiotic stewardship in COVID-19/ARDS ICUs; use WGS when transmission is suspected to rapidly confirm or exclude clonal spread.
Key Findings
- Among 343 ICU patients with COVID-19 pneumonia, diarrhea occurred in 63.8% and CDI in 2.3% (8/343).
- WGS detected no patient-to-patient transmission and outperformed HMW typing for relatedness assessment.
- CDI burden remained low despite pandemic-related care disruptions.
Methodological Strengths
- Application of whole genome sequencing to assess transmission dynamics
- Multicenter ICU cohort with systematic assessment of diarrhea and CDI testing
Limitations
- Retrospective design limits causal inference
- Only eight CDI cases, limiting statistical power and risk factor analysis
Future Directions: Prospective, WGS-integrated surveillance to detect micro-outbreaks; evaluate antibiotic exposure, immunomodulators, and ICU practices as CDI risk factors in ARDS cohorts.
BACKGROUND: The Coronavirus Disease 2019 (COVID-19) pandemic challenged several of the well-known routines to prevent Clostridioides difficile infection (CDI) in intensive care units (ICUs). There are limited data evaluating CDI in ICU patients with COVID-19 pneumonia and acute respiratory distress syndrome. The objective of this study was to determine the occurrence of CDI and possible transmission of C. difficile within three ICUs in patients with COVID-19 pneumonia. METHODS: A retrospective analysis was conducted on all patients with confirmed COVID-19 pneumonia treated in the ICU between 14 March 2020 and 31 July 2021. All patients were assessed for the presence of diarrhoea, as well as for positive C. difficile antigen analysis. C. difficile isolates underwent high molecular weight (HMW) typing and whole genome sequencing (WGS) for the assessment of transmission. RESULTS: A total of 343 patients were treated in the ICUs during the study period. Diarrhoea was observed in 219 (63.8%) patients, and 8 patients (2.3%) were diagnosed with CDI. No evidence of transmission between patients was seen. CONCLUSION: This study reveals a low occurrence of CDI in ICU patients with COVID-19 pneumonia. WGS was superior to HMW-typing in evaluating potential transmission.
2. Clostridioides difficile infection in patients with COVID-19 pneumonia - Analysis of occurrence and genetic distribution from three intensive care units.
Using WGS, investigators found no genomic links among CDI cases in three COVID-19/ARDS ICUs, indicating sporadic rather than nosocomial spread. The work illustrates practical superiority of WGS over HMW typing for transmission investigation in critical care settings.
Impact: Demonstrates operational use of WGS for real-world CDI transmission investigations, refining infection control toolkits during respiratory pandemics.
Clinical Implications: In suspected CDI clusters in ICUs, prioritize WGS to confirm or refute transmission and tailor isolation and cleaning responses accordingly.
Key Findings
- No genomic evidence of CDI transmission among ICU patients with COVID-19/ARDS when assessed by WGS.
- WGS provided higher resolution than HMW typing for determining relatedness of C. difficile isolates.
- Findings support sporadic CDI cases and targeted, not broad, outbreak responses.
Methodological Strengths
- Parallel use of WGS and HMW typing enabling direct methodological comparison
- Unit-wide inclusion of all confirmed COVID-19 pneumonia ICU patients
Limitations
- Small number of CDI cases challenges external validity of transmission inferences
- Lack of standardized antibiotic exposure quantification
Future Directions: Integrate real-time WGS into infection control workflows and assess cost-effectiveness; expand to non-COVID ARDS ICUs to generalize findings.
BACKGROUND: The Coronavirus Disease 2019 (COVID-19) pandemic challenged several of the well-known routines to prevent Clostridioides difficile infection (CDI) in intensive care units (ICUs). There are limited data evaluating CDI in ICU patients with COVID-19 pneumonia and acute respiratory distress syndrome. The objective of this study was to determine the occurrence of CDI and possible transmission of C. difficile within three ICUs in patients with COVID-19 pneumonia. METHODS: A retrospective analysis was conducted on all patients with confirmed COVID-19 pneumonia treated in the ICU between 14 March 2020 and 31 July 2021. All patients were assessed for the presence of diarrhoea, as well as for positive C. difficile antigen analysis. C. difficile isolates underwent high molecular weight (HMW) typing and whole genome sequencing (WGS) for the assessment of transmission. RESULTS: A total of 343 patients were treated in the ICUs during the study period. Diarrhoea was observed in 219 (63.8%) patients, and 8 patients (2.3%) were diagnosed with CDI. No evidence of transmission between patients was seen. CONCLUSION: This study reveals a low occurrence of CDI in ICU patients with COVID-19 pneumonia. WGS was superior to HMW-typing in evaluating potential transmission.
3. [Impact of antenatal corticosteroids on respiratory morbidities in late preterm infants born to mothers with gestational diabetes mellitus].
In 1,420 late preterm infants born to mothers with gestational diabetes, ACS reduced TTN and the need for mechanical ventilation within 24 hours but did not reduce neonatal RDS. The greatest benefit occurred with a complete ACS course and >7 days from first dose to delivery.
Impact: Clarifies ACS benefits and limits in a high-risk subgroup (GDM), refining perinatal respiratory risk reduction strategies beyond generalized recommendations.
Clinical Implications: For late preterm deliveries in mothers with GDM, consider ACS with attention to course completion and timing (>7 days before delivery) to reduce TTN and early ventilation, while recognizing no reduction in RDS and balancing maternal glycemic risks.
Key Findings
- ACS was associated with a lower need for mechanical ventilation within 24 hours after birth.
- ACS did not reduce the incidence of neonatal RDS in late preterm infants of mothers with GDM.
- A complete ACS course and >7-day interval from first dose to delivery provided the greatest reduction in TTN and early mechanical ventilation.
Methodological Strengths
- Large single-center cohort (n=1,420) with multivariable logistic regression
- Clear operationalization of early postnatal outcomes (TTN, RDS, mechanical ventilation within 24 hours)
Limitations
- Retrospective design with potential residual confounding (e.g., glycemic control, obstetric indications)
- Single-center setting may limit generalizability
Future Directions: Prospective studies to optimize ACS timing/dosing in GDM, incorporate maternal glycemic data, and evaluate neonatal respiratory outcomes and metabolic adverse effects.
OBJECTIVES: To investigate the effect of antenatal corticosteroids (ACS) on the risk of transient tachypnea of the newborn (TTN) and respiratory distress syndrome (RDS) within 24 hours after birth in late preterm infants born to mothers with gestational diabetes mellitus (GDM). METHODS: Clinical data of mothers with GDM and their late preterm infants admitted to the Department of Obstetrics, Xiamen Maternal and Child Health Hospital, from January 2017 to December 2023 were retrospectively reviewed. Based on whether mechanical ventilation was required within 24 hours after birth, infants were classified into a mechanical ventilation group ( RESULTS: A total of 1 420 infants were included. Multivariable logistic regression showed that ACS administration was a protective factor against the need for mechanical ventilation within 24 hours after birth ( CONCLUSIONS: ACS does not reduce the incidence of RDS in late preterm infants of mothers with GDM, but it effectively reduces TTN and the need for mechanical ventilation within 24 hours after birth. A complete ACS course and an interval of >7 days from the first dose to delivery provide the greatest benefit in reducing TTN and early postnatal mechanical ventilation.